Why does life use only "left-handed" amino acids? Two chemists just won the Nobel Prize for showing how one molecular hand can take over. Read the story, then see how far you can tip the balance.
On Wednesday, 7 October 2026, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry to Henri B. Kagan and Kenso Soai "for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis." That phrase sounds heavy, but the idea behind it is surprisingly intuitive, and it touches one of the oldest open questions in science: why the molecules of life come in only one of two mirror-image forms.
Heiner Linke, who chairs the Nobel Committee for Chemistry, summed up the laureates' contribution as solving "a chemical mystery that is over a century old," namely how homochirality can arise on its own.
Hold up your two hands. They are made of the same parts in the same order, yet you can't stack one perfectly on top of the other: thumbs end up on opposite sides. Chemists call this property chirality, from the Greek word for "hand." A chiral molecule and its mirror image are called enantiomers.
The most common source of chirality is a carbon atom bonded to four different groups. Swap any two of those groups and you get the mirror-image version. The two enantiomers have the same formula, the same melting point and the same boiling point, but they can behave very differently when they meet other chiral things, such as the receptors in your nose or the enzymes in your liver.
A 50:50 blend of both hands is a racemic mixture. When one hand is in surplus, chemists measure the surplus as enantiomeric excess (ee): the percentage of the majority form minus the percentage of the minority form. A 75:25 mixture therefore has 50% ee, while a pure single enantiomer has 100% ee.
Ordinary chemistry in a flask, without any chiral helper, makes both hands in equal amounts. Living things don't play fair. The proteins in every organism on Earth are built almost entirely from L-amino acids, and the sugars in DNA and RNA are of the D form. This single-handedness is called homochirality, from the Greek for "same hand."
So where did the first imbalance come from, and how did it grow into near-total dominance? Physical nudges such as polarized light or chiral crystal surfaces can produce tiny excesses, but tiny is the key word. Something had to amplify them.
Born in Boulogne-Billancourt, near Paris, in 1930, Henri Kagan studied at the Sorbonne and earned his doctorate from the Collège de France in 1960. He spent nearly four decades at Université Paris-Sud in Orsay, where he became a pioneer of asymmetric catalysis: using a chiral catalyst so that a reaction favors one mirror-image product over the other. In 1971 he introduced DIOP, a chiral molecule that binds to a metal catalyst and steers its reactions, a design idea that shaped later generations of catalysts.
Chemists long assumed a straight-line rule. If your catalyst is only 50% ee, you should get product with roughly half the ee you'd get from a pure catalyst. In 1986 Kagan and his co-workers published experiments, including an asymmetric epoxidation, in which that rule broke. The products could be more enantiomerically pure than the "impure" catalyst predicted. He named the phenomenon a non-linear effect (NLE) and developed mathematical models to explain it.
That "mixed pairs get sidelined" idea is exactly Frank's mutual inhibition, the third ingredient of his amplification recipe. Kagan's discovery also became a practical diagnostic: by checking whether a reaction shows an NLE, chemists can learn whether one catalyst molecule or a cluster of them is doing the work.
Kagan proved that molecular asymmetry could be amplified. Kenso Soai of the Tokyo University of Science went after something even bolder: a reaction where the chiral product is also the catalyst for its own production. That is asymmetric autocatalysis, and in 1995 Soai's team reported it in the journal Nature.
In the reaction now called the Soai reaction, diisopropylzinc adds to pyrimidine-5-carbaldehyde to form a chiral pyrimidyl alcohol. That alcohol then catalyzes the same reaction, and it favors making copies with its own handedness. Each new molecule of the majority hand becomes another catalyst, so the majority snowballs. Soai's group showed that, over consecutive rounds, a product with an extremely low ee could be pushed above 99.5% ee.
Coral = majority hand, teal = minority hand. Illustrative proportions only.
The most striking experiments came later. When Soai's team ran the reaction without any chiral additive, the random statistical imbalance present in any batch was still amplified, giving one hand or the other in high excess, apparently at random. They also found that molecules whose only "handedness" came from swapping a carbon-12 atom for carbon-13 could still tip the outcome. The reaction is extraordinarily sensitive to even the faintest chiral signal.
It is also famously picky. It works with diisopropylzinc and pyrimidine-type aldehydes but not with close cousins such as diethylzinc, and chemists spent about 25 years unpicking its mechanism. Researchers such as Donna Blackmond at Scripps Research and Scott Denmark at the University of Illinois helped explain the kinetics and the molecular clusters behind the amplification.
Together, non-linear effects and asymmetric autocatalysis show a concrete, testable way that a tiny chance imbalance can grow into near-complete single-handedness. The Soai reaction itself isn't something that happened on the early Earth, but it proves the principle works with real molecules, not just on paper. How life's homochirality actually arose is still debated, and this work narrows the search.
Because your body is chiral, the two hands of a drug can act differently. The thalidomide tragedy of the late 1950s and early 1960s is the classic warning: one form was linked to the sedative effect and the other to severe birth defects. (A sobering detail is that thalidomide converts between its two forms inside the body, so a "pure" version would not have been safe either.) Today many medicines are made as single enantiomers, and understanding catalyst behavior, including NLEs, helps chemists make them efficiently.
This is the third Chemistry Nobel in 25 years connected to controlling molecular handedness, after asymmetric catalysis in 2001 and asymmetric organocatalysis (Benjamin List and David MacMillan) in 2021. The 2026 prize adds the missing piece: how handedness can amplify itself.
Your answers are your catalyst. You start as a perfectly racemic 50:50 mixture. Every correct answer amplifies your majority hand, Soai-style. Can you reach 99.5% ee?
Henri B. Kagan of France and Kenso Soai of Japan, announced on 7 October 2026. They share the prize equally for discovering non-linear effects and autocatalysis in asymmetric organic synthesis.
It's when a chiral catalyst that is only partly "one-handed" produces a product that is much more (or less) one-handed than you'd expect from a simple straight-line relationship. Kagan first described it in 1986.
Its chiral product catalyzes its own formation and favors copies of its own hand, so a tiny initial excess can be amplified to over 99.5% ee in a few rounds. It was reported in 1995.
No. It shows a realistic chemical mechanism by which a small imbalance can become overwhelming, which makes the idea testable. Exactly which chemistry happened on the early Earth is still an open research question.
Receptors and enzymes in the body are themselves chiral, so the two hands of a drug can have different effects, strengths or side effects. That's why chemists work hard to make single enantiomers.
Each 2026 Nobel Prize is worth 12 million Swedish kronor (about US$1.2 million), split between the laureates. The award ceremony takes place in Stockholm on 10 December 2026.
Editorial note: This article was written for general readers and checked against the Nobel Prize announcement, the Nobel Committee's scientific background and the laureates' original papers. Last updated 9 October 2026. Spot an error? Let us know and we'll correct it.